Patents by Inventor Niu Huang
Niu Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230382098Abstract: The disclosure provides a method for fabricating a cantilever section in a structure, which includes providing a structure comprising a substrate, a compliant layer and a sacrificial layer therebetween; cutting part-way through the substrate to create an at least one linear partial cut; releasing the sacrificial layer from the structure; and breaking the substrate along the at least one linear partial cut to generate a cantilever section in a substrate.Type: ApplicationFiled: May 31, 2022Publication date: November 30, 2023Applicant: Neuralink Corp.Inventors: Yu Niu Huang, Peter J. Gilgunn, Dominic A. Herincx, Zachary M. Tedoff
-
Monolithic, biocompatible feedthrough for hermetically sealed electronics and methods of manufacture
Patent number: 11107703Abstract: Methods of manufacturing a biocompatible, hermetic feedthrough monolithically integrated with a biocompatible ribbon cable are described, as well as the resulting devices themselves. The hermetic feedthrough is created by placing glass over a mold of doped silicon or other material with a higher melting temperature than the glass and heating it to reflow the glass into the mold. The glass is then ground or otherwise removed to reveal a flat surface, and tiny pillars that were in the mold are isolated in the glass to form electrically conductive vias. The flat surface is used to cast a polymer and build up a ribbon cable, photolithographically or otherwise, that is monolithically attached to the vias.Type: GrantFiled: July 9, 2020Date of Patent: August 31, 2021Assignee: Neuralink Corp.Inventors: Vanessa M. Tolosa, Camilo A. Diaz-Botia, Supin Chen, Felix Deku, Yu Niu Huang, Mark J. Hettick, Zachary M. Tedoff -
Publication number: 20210238127Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: ApplicationFiled: April 18, 2021Publication date: August 5, 2021Applicant: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Shiming Peng
-
Patent number: 10988440Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: GrantFiled: January 12, 2020Date of Patent: April 27, 2021Assignee: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Shiming Peng
-
Patent number: 10980766Abstract: The invention provides use of entacapone, an entacapone derivative or a stereoisomer, hydride, or pharmaceutically-acceptable salt thereof, in a person in need thereof, to treat or inhibit macular degeneration or age-related macular degeneration, and related compostions.Type: GrantFiled: February 22, 2019Date of Patent: April 20, 2021Assignee: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Shiming Peng
-
Monolithic, Biocompatible Feedthrough for Hermetically Sealed Electronics and Methods of Manufacture
Publication number: 20210013051Abstract: Methods of manufacturing a biocompatible, hermetic feedthrough monolithically integrated with a biocompatible ribbon cable are described, as well as the resulting devices themselves. The hermetic feedthrough is created by placing glass over a mold of doped silicon or other material with a higher melting temperature than the glass and heating it to reflow the glass into the mold. The glass is then ground or otherwise removed to reveal a flat surface, and tiny pillars that were in the mold are isolated in the glass to form electrically conductive vias. The flat surface is used to cast a polymer and build up a ribbon cable, photolithographically or otherwise, that is monolithically attached to the vias.Type: ApplicationFiled: July 9, 2020Publication date: January 14, 2021Applicant: Neuralink Corp.Inventors: Vanessa M. Tolosa, Camilo A. Diaz-Botia, Supin Chen, Felix Deku, Yu Niu Huang, Mark J. Hettick, Zachary M. Tedoff -
Patent number: 10682329Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.Type: GrantFiled: June 26, 2018Date of Patent: June 16, 2020Assignee: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
-
Publication number: 20200148628Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: ApplicationFiled: January 12, 2020Publication date: May 14, 2020Applicant: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Shiming Peng
-
Patent number: 10532976Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: GrantFiled: December 22, 2017Date of Patent: January 14, 2020Assignee: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Shiming Peng
-
Publication number: 20190183842Abstract: The invention provides use of entacapone, an entacapone derivative or a stereoisomer, hydride, or pharmaceutically-acceptable salt thereof, in a person in need thereof, to treat or inhibit macular degeneration or age-related macular degeneration, and related compostions.Type: ApplicationFiled: February 22, 2019Publication date: June 20, 2019Inventors: Niu Huang, Shiming Peng
-
Publication number: 20180303788Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.Type: ApplicationFiled: June 26, 2018Publication date: October 25, 2018Applicant: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
-
Patent number: 10004715Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.Type: GrantFiled: January 4, 2014Date of Patent: June 26, 2018Assignee: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
-
Publication number: 20180118665Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: ApplicationFiled: December 22, 2017Publication date: May 3, 2018Applicant: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Shiming Peng
-
Publication number: 20180111908Abstract: The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.Type: ApplicationFiled: December 19, 2017Publication date: April 26, 2018Applicant: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Yu Zhou, Xingyu LIN
-
Patent number: 9845298Abstract: The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.Type: GrantFiled: August 18, 2017Date of Patent: December 19, 2017Assignee: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Yu Zhou, Xingyu Lin
-
Publication number: 20170349559Abstract: The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.Type: ApplicationFiled: August 18, 2017Publication date: December 7, 2017Applicant: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Yu Zhou, Xingyu LIN
-
Patent number: 9751845Abstract: The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.Type: GrantFiled: October 13, 2016Date of Patent: September 5, 2017Assignee: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Yu Zhou, Xingyu Lin
-
Publication number: 20170029385Abstract: The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.Type: ApplicationFiled: October 13, 2016Publication date: February 2, 2017Applicant: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Yu Zhou, Xingyu LIN
-
Publication number: 20140148383Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.Type: ApplicationFiled: January 4, 2014Publication date: May 29, 2014Applicant: NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJINGInventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
-
Publication number: 20070196395Abstract: Small molecular-weight non-peptidic compounds block Lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.Type: ApplicationFiled: December 12, 2003Publication date: August 23, 2007Inventors: Alexander Mackerell, Jun Hayashi, Ashish Nagarsekar, Niu Huang, Alba Macias